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Introduction
Numerous investigations have found that insulin sensitivity (SI) is an important metabolic marker of risk for cardiovascular disease [1] [2] [3] [4] and type 2 diabetes. [5] [6] [7] [8] However, use of SI to investigate the pathophysiology of these conditions has been limited by the lack of a widely accepted insulin sensitivity test that is both economical and accurate. Existing tests involve either intensive highcost protocols that produce reliable SI values or lower intensity protocols that provide less accurate SI values at a lower cost. 9, 10 Surrogate measures of insulin sensitivity derived from oral glucose tolerance test data have exhibited reasonable compromises of cost and accuracy [11] [12] [13] but have not become widely used.
The dynamic insulin sensitivity and secretion test (DISST) was originally developed to provide a means of assessing SI and endogenous insulin secretion (U N ) with a favorable compromise of economy and accuracy. [14] [15] [16] Subsequent investigation has shown that the cost of the original DISST could be significantly reduced by eliminating the insulin and C-peptide assays with only a moderate associated reduction in accuracy. 17, 18 Using only glucose measurements, the quick dynamic insulin sensitivity test (DISTq) is able to identify SI in real time. 17, 18 Although the DISTq can generate participant-specific SI values at a substantially lower cost, the standard DISST provides metrics of both SI and U N to provide a comprehensive observation of the participant's metabolic health.
The DISST and DISTq use two very distinct assay protocols with different trade-offs on cost and accuracy of SI and U N identification. However, numerous variations of the standard DISST-based assay regimens could potentially provide tests with optimal compromises of information yield, assay cost, metric accuracy, and clinical intensity for a number of potential clinical applications. This article describes eight such variations that utilize the standard DISST protocol, and presents their accuracy in terms of repeating the findings of the fully sampled DISST 15 in a moderately insulin-resistant cohort. 19 
Methods

Participants
Eighty-two female participants from the Otago region of New Zealand took part in a 10-week dietary intervention trial described by Te Morenga and colleagues. 19 Inclusion criteria required that participants either had a body mass index greater than 25, or greater than 23 and a family history of type 2 diabetes, or ethnic disposition toward type 2 diabetes. Participants were excluded if they had a major illness, including established diabetes, at the time of testing. In total, 74 subjects provided 218 full DISST data sets. Participant characteristics are summarized in Table 1 . Ethical approval for this study was granted by the University of Otago Ethics Committee.
DISST Protocol
The DISST was conducted at weeks 0, 4, and 10 of the intervention by a research nurse under medical supervision. Participants attended the test after a 10-12 h fast and remained in a seated position for the test's duration. Samples were drawn at t = 0, 5, 10, 15, 20, 25, 30, 35 , and 45 min through a cannula that was inserted into the antecubital fossa. A 10 g bolus of intravenous glucose containing 50% dextrose and 50% normal saline was given via the same cannula within 1 min after the fasting sample. One unit of insulin (Actrapid ® , Novo Nordisk, Copenhagen, Denmark) was given immediately after the 10 min sample. Immediately after drawing each blood sample, the cannula was flushed with 1-2 ml normal saline to prevent clotting. Approximately 3 ml of blood were withdrawn to remove the saline just prior to taking each blood sample. Samples were collected into separate vacutainers containing coagulant for measurement of insulin and C-peptide, and fluoride and oxalate anticogulants for measurement of glucose concentrations.
Whole blood samples were centrifuged at 1650 g for 15 min, and then the plasma was pipetted into polyethylene cryovials and stored at -80 °C for up to 12 months. At the completion of the data collection period, laboratory analyses of all assays were performed by batch to minimize laboratory measurement bias. Serum insulin and C-peptide were measured using a specific insulin electrochemiluminescence immunoassay (Roche, Catalog Number 12017547) for the Elecsys ® analyzer (Roche Diagnostics, Mannheim, Germany) after polyethylene glycol precipitation of immunoglobulins, with a coefficient of variation of 1.5%. Plasma glucose was measured enzymatically with Roche kits and calibrators on a Cobas Mira ® analyzer (Hexokinase Catalog Number 11447513216, Roche, Mannheim, Germany) with a coefficient of variation of 0.5%.
Design Strategy of the Various Proposed Protocols
Eight variations of the standard DISST sampling and assay protocol were evaluated by their ability to reproduce the SI and U N values identified by the fully sampled DISST (DISST-FS). 15 Each variation uses different sampling and assay regimens to provide a distinct compromise of economy, accuracy, and information. Sample omissions effectively reduce clinical effort and intensity by skipping some DISST-FS scheduled blood samples. Assay omissions still require the same blood samples but only one or two species are assayed to minimize overall assay cost. Five of the sampling protocols were based on DISTq identification methods. 17 Thus, these protocols could not provide estimates of patient-specific first and subsequent pass hepatic extraction (x L and n L , respectively) and U N values.
DISST-FS
DISST-FS is a low-dose, short-duration insulin modified intravenous glucose tolerance test. [14] [15] [16] 20 The DISST modeling approach has enabled high accuracy insulin sensitivity and insulin secretion metrics to be derived from a 45 min, nine-sample protocol that is less frequently sampled than established dynamic protocols. It utilizes C-peptide, insulin, and glucose assays from every available sample time.
Short
The Short protocol was designed to capture the major dynamics of C-peptide, insulin, and glucose responses with reduced overall test time and fewer samples.
DISST-E/SI
The DISST-E/SI identification method uses six glucose, six insulin, and three C-peptide assays from seven samples. Three significant metrics can be derived from typical U N profiles: the basal insulin production rate (U B ), the firstphase secretion (U 1 ), and the second-phase production (U 2 ). Only three C-peptide assays are required to directly and uniquely identify these rates.
Sparse
The Sparse protocol was designed to reduce clinical intensity by taking only three samples to define the three major U N metrics and SI. The second sample taken 5 min after the glucose bolus in the DISST-FS is subject to incomplete mixing of the glucose bolus in the bloodstream [14] [15] [16] [17] [18] [19] [20] [21] and is thus not used to define the participant's specific glucose distribution volume (V G ). A proportion (29%) of the participant's lean body mass (LBM) 22 is used to estimate V G in this protocol.
DIST-SI
DIST-SI identifies SI but not U N , thus it does not require C-peptide assays. Population-based parameter estimations from the DISTq 17 were used to estimate the U N profiles based on the participants' SI values. The DISST nomenclature is reduced to DIST when insulin secretion values are not reported.
DIST-SI-2
DIST-SI-2 involves further simplification of the DIST-SI protocol by taking fewer samples and performing fewer assays than the DIST-SI protocol. The period of greatest importance to SI identification is the later part of the test protocol. Thus, only two samples, taken at the end of the test, were assayed for insulin, while the full glucose response was observed with four glucose assays.
DISTq-FS
DISTq-FS requires eight glucose assays to define SI in an iterative identification process. 17, 18 The method estimates the participant's endogenous insulin production and insulin pharmacokinetics with a series of functions of the participant's SI and anatomical data (height, weight, age, and sex). 23 Thus, the method is a posteriori and iterative in nature.
DISTq-S
This protocol is a simplification of the Short DIST specifically and uses only four glucose assays to define a value for SI. The second sample (at t = 5) is not assayed for this identification method. However, this sample may allow for later assays of the insulin or C-peptide to increase resolution of the insulin concentration reconstruction or obtain metrics of first-phase insulin production.
DISTq30
DISTq30 identifies SI using very sparse data (two glucose assays only). Functions of the participant's LBM are used to define the glucose distribution volume in the absence of measured data. Table 2 shows the sampling and assay protocols used by each protocol. Table 3 summarizes the clinical burden of the tests in terms of protocol duration and assay cost as well as the potential outcomes. Assay costs in New Zealand are approximately $2.50 for glucose, $25 for insulin, and $35 for C-peptide (NZ$).
The homeostasis model assessment (HOMA) metric is included to provide context and comparison to the DISST-based outcomes.
SI and U N Identification Methods
Insulin sensitivity and secretion metrics are defined by identifying parameters of a physiological model against DISST test data. The model is presented in detail by Lotz and colleagues. [14] [15] U N profiles are either defined using deconvolution (DC) when C-peptide assays are available or the population-based estimates of the DISTq method (E DISTq ) when C-peptide assays are not available. The DC method was developed by Eaton and colleagues. 24 and validated by Van Cauter Table 2 .
Proposed Sample and Assay Schedules for Glucose (G), Insulin (I), and C-Peptide (C). S Denotes a Sample that is Drawn and Stored but Not Assayed
Assay regimen Assays   0  5  10  15  20  25  30  35  45  G  I  C   DISST-FS  GIC  IC  GIC  GC  GIC  GIC  GIC  GIC  GIC  8  8  9   Short  GIC  IC  GIC  -GIC  -GIC  --4  5  5 DISST -E/SI  GIC  IC  GI  G  GIC  GI  GI  --6  6  3   Sparse  GIC  IC  ---GIC  ---2  3  3   DIST-SI  GI  I  GI  G  GI  GI  GI  --6 6 0 and colleagues. 23 It has been used with the DISST test data 14, 20, 25 and proven robust to assay omissions. 26 The DISTq identification methods and population-based estimates have been published elsewhere. 17, 18 The identification of U N metrics from the DISST-E/SI data requires a slight variation on the stated DC approach as the final blood sample of the DISST-E/SI is not assayed for C-peptide. Thus, the U N rate is assumed constant after the final C-peptide assay.
Plasma and interstitium insulin concentrations are defined using either the iterative integral method (IIM) 17, 27 or the DISTq estimation methods (E DISTq ). 17, 18 The IIM identifies participant-specific values of n L and x L to simulate the observed insulin pharmacokinetics and simulated profiles of insulin in the two compartments. The DISTq method uses the population-based parameter estimation equations to define n L as a function of SI and sets x L to a population constant (70%). [28] [29] [30] These values are used to simulate the participant's insulin concentration in the plasma and interstitium. Note that the DIST-SI-2 uses the DISTq parameter estimation for basal insulin (I b ) and IIM to identify n L with a fixed x L .
SI and V G are identified using the IIM. However, the Sparse and DISTq30 protocols do not have sufficient glucose data to identify V G . In these cases, V G is estimated as a proportion (29%) of LBM as calculated by Hume. 22 The value of 29% was defined using linear regression of the V G value identified from DISST-FS data to LBM in an isolated cohort. 
Analysis
DISST-FS data (n = 218) with appropriate assay omissions will be used to directly identify SI and U N using the standard DISST-FS method 15 and the eight DISST-based variants. The SI, U B , U 1 , and U 2 values from the alternative protocols were compared to the corresponding values obtained by the DISST-FS using Pearson's correlation coefficients and quartiles of the proportional differences (∆). The proportional differences will be defined with Equation (1).
( 1) where V P is the value defined by the DISST-based variant and V FS is the DISST-FS value.
The simple HOMA insulin sensitivity index was also calculated from plasma insulin and glucose assays derived from the fasting blood samples taken during each DISST-FS. The correlation between HOMA and DISST-FS is presented for comparison.
Results
The accuracy and information produced by the tests were intrinsically linked to assay cost and clinical burden. Table 5 summarizes the performance of all proposed protocols with respect to their ability to replicate the SI and U N values identified using the DISST-FS. The sparser DIST-SI-2 method showed the greatest ability to replicate the SI metrics of the DISST-FS. It was closely followed by DIST-SI, Short protocol, DISST-E/SI, and Sparse protocol. DISTq-S and DISTq30 correlated highly to DISTq-FS at r = 0.94 and r = 0.89, respectively. Despite a substantial reduction in the number of assays, the DISTq30 estimates of insulin sensitivity were highly correlated with the DISTq-FS (r = 0.89) with limited bias (-4.2%), thus providing validation for the LBM-based estimation of V G .
Protocols that assayed C-peptide from the t = 0 and t = 5 min samples generated the same measures of U B and U 1 to those generated by the DISST-FS, as expected.
Reducing the number of C-peptide samples had a greater effect on U 2 . DISTq was not intended for estimation of U N metrics.
The correlations between HOMA and the insulin sensitivity metrics of DISST-FS were weaker than correlations between the DISST-FS and all alternative DISST-based protocols.
Discussion
Relatively high SI correlations (r ~0.9) and a lack of bias (Q2 bias range -17.9 to 7.8%) between the protocols that assayed insulin and the DISST-FS test show that the limited sampling protocols could be used as low-cost alternatives to the fully sampled test without significantly diminishing test resolution. In particular, the Sparse protocol insulin sensitivity values identified using only three samples correlated well to the fully sampled test (r = 0.84) and also captured all major dynamics of the U N profile. This is despite the protocol requiring just over half the time and one third of the assay cost. DISTq provided accurate estimates of SI values that compared favorably with estimates generated by more intense and costly fully sampled methods. The DISTq-FS method performed in accordance with published findings. DISTq-S and DISTq30 also correlated relatively well to the DISST-FS, particularly in comparison with the wellaccepted HOMA, which performed poorly.
Overall, the findings of the spectrum analysis show the considerable robustness of the DISST model-based SI metric to significant assay omissions. While the highest possible accuracy is achieved with the most frequently sampled tests and comprehensively assayed samples, reducing the sample resolution only has a mildly deleterious effect on the accuracy of the insulin sensitivity outcomes.
Sampling regimens that utilized C-peptide measurements produced insulin secretion metrics that were highly correlated to the DISST-FS despite reductions in sampling. Lotz and colleagues 26 found a similar robustness of endogenous insulin production metrics to assay omission. In particular, the Sparse protocol has shown that most of the insulin secretion information obtained from nine C-peptide assays can be obtained with only three [r(U B ) = 1, r(U 1 ) = 1, r(U 2 ) = 0.88]. As C-peptide assays contribute to a significant portion of the standard DISST assay cost, considerable cost savings are enabled by the robustness of the model to assay omissions. Protocols that utilized DISTq estimation methods were not intended to accurately predict participant-specific values of insulin secretion. Thus, the poor correlation is not considered a negative result and the minimal bias indicates that the general magnitude of prediction was accurate at a cohort level.
The participant inclusion criteria led to selection of a cohort that tended toward the insulin-resistant range. As correlations measure variable spread as well as linearity, 31 it is likely that the correlations reported for this targeted cohort are less than would be identified with the same analysis undertaken with a general cohort. Furthermore, the insulin secretion metrics of insulinresistant participants are much more variable than those of sensitive individuals. 17, 18, 32 This investigation used clinical data from the same test procedure to analyze each DISST-based test and HOMA. Thus, the effects of participant variation between tests, which reduces the equivalence measured by most intertest investigations, did not affect the outcomes of Table 5 . this analysis. Furthermore, assay error had a distinct and lesser impact on this analysis compared to normal intertest investigations. In particular, assay error may cause the over-and underestimation of subsequent test outcomes in typical intertest investigations, whereas assay error in this analysis only varied the outcomes between tests when there were distinct assay regimens within a species. Intraindividual repeatability was not assessed in this study. The original data was from a 10-week dietary intervention study in which significant changes in SI were expected for half the cohort and limited changes for the control group. Thus, true SI changes, or the lack thereof, across subjects would be arguable. Equally, the time between tests of 10 weeks would, even for the control group, also include other natural variations. A properly designed repeatability investigation would focus on multiple tests over 3-7 days to mitigate these issues, which was not the case here. Optimal numbers of test participants could be recruited for lower resolution investigations of insulin sensitivity and secretion by using the DISST-based tests that provide a compromise between cost and resolution. For example, investigations that aim to measure the effects of a particular dietary intervention on a number of physiological markers including insulin sensitivity, the DIST-SI-2 protocol may be appropriate. In contrast, cost-restrictive pathophysiological studies of type 2 diabetes with large insulin-resistant cohorts should perhaps utilize the low cost but informative Sparse protocol, which can also produce β-cell function estimates.
Correlations and Quartiles of Proportional Differences of SI and U N Values Identified with the Proposed Protocols and the DISST-FS
The DISTq test could also be used to measure the efficacy of intervention provided the intervention was expected to have a minimal effect on the participant's insulin clearance rates and insulin production response to the DISST stimulus. The DISTq SI identification process estimates the participant's insulinemic response to test stimulus rather than observing it through insulin or C-peptide assays. Thus, changes in glucose decay as a result of shifts in the participant's insulinemic response will be incorrectly attributed to SI by the DISTq identification process. However, the DISTq tests would be suitable for tracking SI changes provided that consistency in insulin clearance and insulin production can be reasonably assumed for the duration of the intervention.
Finally, the various sampling schedules could allow more assays from the samples taken to enable higher resolution analyses, or less assays to be performed to reduce overall cost. The DISST-based hierarchy does not require an additional clinical procedure to be undertaken to increase the SI resolution. For example, the DIST-SI protocol requires seven blood samples, which yield six glucose and six insulin assays. If cost savings were desired, only two glucose assays could be undertaken on the available samples and the DISTq30 could provide a comparatively low resolution SI result. However, if this result was close to a diagnostic threshold and a more accurate diagnosis were desired, stored samples could be reassayed. Further assays of insulin and/or C-peptide, as well as glucose when not done previously, could result in a higher resolution SI value using the DIST-SI method, or a DISST-S result that includes participant-specific U N metrics. This approach increases storage costs but minimizes cost for participants who can be diagnosed with a lower resolution test. Table 6 shows all potential sample schedules and subsequent possible assay and identification methods for each sampling protocol defined. 
Conclusions
The DISST-based spectrum of tests utilizes the robustness of the model-based insulin sensitivity and secretion metrics to the omission of assays to provide a series of tests that encompass a wide range of compromises between economy and accuracy. Thus, researchers could potentially select the best DISST-based test for a wide range of clinical applications. In particular, the more intensely sampled and assayed tests could offer comprehensive metabolic information, while the low-cost tests could enable screening applications that were inhibited by the poor resolution of low-cost insulin sensitivity surrogates.
The tests that compromise accuracy and cost could potentially allow an optimal number of participants to be tested in clinical trials, thus making the best use of available funds.
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